TGFB1 and Hepatic fibrosis: FFBJRG pill inhibited hepatic fibrosis in vitro and in vivo by inhibiting TGF-β1/SMAD pathway transduction [107] and is currently in phase IV clinical trials in the United States for the treatment of chronic HBV infection-associated liver fibrosis [108].